Cancer Treatment Reviews
Volume 30, Issue 6 , Pages 589-593 , October 2004

Autologous tumour cell vaccine may reduce risk of tumour progression in people with primary renal cell carcinoma: Abstracted from: Jocham D, Richter A, Hoffmann L et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004;363:594–599.

References 

  1. Gleave ME, Elhilali M, Fradet Y, et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. N. Engl. J. Med. 1998;338:1265–1271
  2. Coppin C, Porzsolt F. Kidney cancer. In:  Williams C editors. Evidence-Based Oncology. London: BMJ Books; 2003;(Chapter 30)
  3. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J. Sci. Am. 2000;6(Suppl 1):S55–S57
  4. Pizzocaro G, Piva L, Colavita M, et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomised study. J. Clin. Oncol. 2001;19:425–431
  5. Clark JI, Atkins MB, Urba WJ, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a Cytokine Working group Randomized Trial. J. Clin. Oncol. 2003;21:3133–3140
  6. Galligioni E, Quaia M, Merlo A, et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and Bacillus Calmette-Guerin. Cancer. 1996;77:2560–2566

☆ Sources of funding: LipoNova (Hannover, Germany).

☆ For Correspondence Prof. Dieter Jocham, Department of Urology, University of Lubeck Medical School, Ratzeburger Allee 160, 23538 Lubeck, Germany. E-mail: prof.jocham.mul@t-online.de.

☆☆☆ Abstract provided by Bazian Ltd., London.

PII: S0305-7372(04)00122-7

doi: 10.1016/j.ctrv.2004.06.006

Cancer Treatment Reviews
Volume 30, Issue 6 , Pages 589-593 , October 2004

Article Tools